Clinical bottom line
Pediatric sudden onset sensorineural hearing loss (SSNHL) remains a rare but urgent otologic emergency requiring prompt diagnosis and intervention to optimize hearing recovery. Recent evidence highlights evolving diagnostic strategies emphasizing early imaging and audiometric evaluation, alongside emerging therapeutic options including corticosteroids and hyperbaric oxygen therapy. However, pediatric SSNHL poses unique challenges due to heterogeneous etiology, variable presentation, and limited high-quality pediatric-specific trials. Clinicians should maintain a high index of suspicion, initiate timely corticosteroid treatment, and consider adjunctive therapies on a case-by-case basis while awaiting further validation of novel approaches.
What the evidence shows
Pediatric SSNHL is defined as a rapid onset sensorineural hearing loss of at least 30 dB over three contiguous frequencies occurring within 72 hours. Although less common than in adults, it warrants urgent evaluation due to potential long-term auditory and developmental sequelae (Hanson et al., 2026). Etiologies are diverse and include viral infections, vascular insults, autoimmune processes, and perilymphatic fistula, with many cases remaining idiopathic despite thorough workup (Herrera et al., 2024a; Herrera et al., 2024b).
Diagnostic assessment prioritizes detailed audiometry and magnetic resonance imaging (MRI) to exclude retrocochlear pathology and identify inner ear inflammation or vascular compromise (Rodríguez Izquierdo et al., 2024; Herrera et al., 2024a). MRI with gadolinium contrast is increasingly recommended early in the diagnostic pathway to detect labyrinthine enhancement or cochlear nerve abnormalities, which may guide prognosis and management (Herrera et al., 2024a).
Therapeutically, systemic corticosteroids remain the mainstay, with early initiation associated with improved hearing outcomes (Hanson et al., 2026; Luu et al., 2023). However, there is no consensus on optimal dosing or duration in children, and treatment protocols are often extrapolated from adult data (Luu et al., 2023). Adjunctive intratympanic steroid injections are used in refractory cases but lack robust pediatric-specific evidence.
Emerging evidence supports hyperbaric oxygen therapy (HBOT) as a promising adjunct, potentially enhancing cochlear oxygenation and recovery, though pediatric data are limited and largely observational (Shaheen et al., 2024). HBOT may be considered in select cases, especially when corticosteroid response is suboptimal.
Practice patterns vary widely, reflecting diagnostic uncertainty and limited pediatric-focused guidelines (Luu et al., 2023). Multidisciplinary collaboration involving otolaryngology, audiology, and radiology is critical for comprehensive care.
Caveats and uncertainty
The rarity of pediatric SSNHL and heterogeneity in etiology complicate the establishment of standardized diagnostic and treatment algorithms. Most evidence derives from small case series, retrospective cohorts, or adult extrapolations, limiting generalizability (Dedhia et al., 2016; Luu et al., 2023). The natural history of untreated pediatric SSNHL is poorly characterized, and spontaneous recovery rates vary widely.
MRI findings such as cochlear enhancement are not universally present and may not correlate perfectly with prognosis (Herrera et al., 2024a). The timing of imaging relative to symptom onset influences sensitivity, and access to pediatric MRI may be limited in some settings.
Corticosteroid regimens lack pediatric-specific randomized controlled trials, and potential side effects warrant cautious use, especially in younger children. The role of intratympanic steroids and HBOT remains investigational, with no consensus on indications, timing, or protocols.
Long-term auditory and developmental outcomes following pediatric SSNHL are underreported, and the impact of early versus delayed intervention on language and cognitive milestones requires further study.
How this may change practice
Clinicians should adopt a high index of suspicion for SSNHL in children presenting with acute hearing changes and expedite audiometric and MRI evaluation to exclude treatable causes. Early systemic corticosteroid therapy remains the cornerstone of management, ideally initiated within days of symptom onset.
Incorporating early MRI into diagnostic pathways may improve etiologic identification and prognostication, facilitating tailored treatment plans. Adjunctive therapies such as intratympanic steroids and HBOT may be considered in refractory or severe cases, though clinicians should counsel families regarding the limited pediatric evidence base.
Standardizing diagnostic and therapeutic protocols through multicenter pediatric registries and prospective studies is needed to reduce practice variability and improve outcomes. Multidisciplinary care models integrating otolaryngology, radiology, audiology, and pediatric neurology may enhance comprehensive management.
Ongoing research into the pathophysiology and optimal treatment of pediatric SSNHL will be essential to refine clinical guidelines and improve long-term auditory and developmental outcomes.